Vitae Pharmaceuticals embraces strategic partnerships to advance the discovery and development of novel, innovative compounds for patients with significant unmet medical needs
We seek collaborations with leading pharmaceutical companies to enhance all aspects of our pipeline development.
- We are seeking a risk-sharing partnership around VTP-27999, our wholly-owned CKD program, to accelerate development and commercialization of our product candidate, which is set to enter Phase 2b trials in 2012.
- We are looking to form a co-development partnership around our LXR program to advance our compounds to the clinic for the treatment of atherosclerosis or Alzheimer's Disease.
- We are actively pursuing a partner for our RORγt program to quickly advance our compounds into preclinical development for Autoimmune Disease.
- We are actively interested in establishing research collaborations with global or regional firms to leverage the speed, efficiency and novelty of our discovery platform to deliver innovative compounds for hard-to-drug targets.
We operate with the firm belief that significant advances in drug discovery, development, and commercialization must come from both inside and outside our company. By selectively and strategically combining ideas and resources with our partners, we can more quickly and effectively develop important drugs for unmet medical needs and bring them to patients sooner.
For more information about partnering with Vitae, please contact email@example.com.